ES3036762T3 - A modulatable switch for selection of donor modified cells - Google Patents

A modulatable switch for selection of donor modified cells

Info

Publication number
ES3036762T3
ES3036762T3 ES22216082T ES22216082T ES3036762T3 ES 3036762 T3 ES3036762 T3 ES 3036762T3 ES 22216082 T ES22216082 T ES 22216082T ES 22216082 T ES22216082 T ES 22216082T ES 3036762 T3 ES3036762 T3 ES 3036762T3
Authority
ES
Spain
Prior art keywords
cells
hprt
approximately
modified
lymphocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES22216082T
Other languages
English (en)
Spanish (es)
Inventor
Christopher Walter Alma
Jeffrey Bartlett
Louis Randall Breton
Geoffrey Phillip Symonds
Ming Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Gene Therapy Pty Ltd
CSL Behring Gene Therapy Inc
Original Assignee
CSL Gene Therapy Pty Ltd
CSL Behring Gene Therapy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Gene Therapy Pty Ltd, CSL Behring Gene Therapy Inc filed Critical CSL Gene Therapy Pty Ltd
Application granted granted Critical
Publication of ES3036762T3 publication Critical patent/ES3036762T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES22216082T 2017-07-18 2018-07-18 A modulatable switch for selection of donor modified cells Active ES3036762T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762533707P 2017-07-18 2017-07-18

Publications (1)

Publication Number Publication Date
ES3036762T3 true ES3036762T3 (en) 2025-09-24

Family

ID=63104099

Family Applications (2)

Application Number Title Priority Date Filing Date
ES22216082T Active ES3036762T3 (en) 2017-07-18 2018-07-18 A modulatable switch for selection of donor modified cells
ES18750006T Active ES2940681T3 (es) 2017-07-18 2018-07-18 Un interruptor modulable para la selección de células modificadas donantes

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES18750006T Active ES2940681T3 (es) 2017-07-18 2018-07-18 Un interruptor modulable para la selección de células modificadas donantes

Country Status (11)

Country Link
US (3) US10426798B2 (enExample)
EP (2) EP4190339B1 (enExample)
JP (1) JP7410856B2 (enExample)
KR (1) KR20200125574A (enExample)
CN (1) CN111343996A (enExample)
AU (1) AU2018304222A1 (enExample)
BR (1) BR112020001132A2 (enExample)
CA (1) CA3070258A1 (enExample)
ES (2) ES3036762T3 (enExample)
SG (1) SG11202000428PA (enExample)
WO (1) WO2019018491A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
EP4190339B1 (en) * 2017-07-18 2025-07-02 CSL Behring Gene Therapy, Inc. A modulatable switch for selection of donor modified cells
SG11202003907WA (en) 2017-12-14 2020-05-28 Flodesign Sonics Inc Acoustic transducer drive and controller
JP2022514954A (ja) * 2018-12-23 2022-02-16 シーエスエル・ベーリング・エルエルシー キルスイッチを有するドナーｔ細胞
WO2021263070A1 (en) * 2020-06-26 2021-12-30 Csl Behring Llc Donor t-cells with kill switch
US20250154457A1 (en) * 2021-03-04 2025-05-15 City Of Hope T-cells for anti-hiv car-t therapy and methods of use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US922105A (en) 1908-10-14 1909-05-18 Axel E Anderson Hoisting apparatus.
ATE145428T1 (de) 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6103521A (en) 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
US5965126A (en) 1996-03-25 1999-10-12 The Penn State Research Foundation use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
WO1997043900A1 (en) 1996-05-24 1997-11-27 The President And Fellows Of Harvard College In vivo selection
AU7605796A (en) 1996-11-04 1998-05-29 Saint Jude Children's Research Hospital (in vivo) selection of primitive hematopoietic cells
ATE439137T1 (de) 1997-11-14 2009-08-15 Gen Hospital Corp Behandlung von hämatologischen störungen
US7094885B2 (en) 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
US20030032003A1 (en) 2000-02-02 2003-02-13 Schiestl Robert H. In vivo selection
CA2428721A1 (en) 2000-11-14 2002-05-23 The General Hospital Corporation Blockade of t cell migration into epithelial gvhd target tissues
US7037900B2 (en) 2001-10-12 2006-05-02 Supergen, Inc. Composition and method for treating graft-versus-host disease
KR20120059581A (ko) * 2009-08-24 2012-06-08 윌슨 울프 매뉴팩처링 다중 종양 항원 또는 다중 바이러스에 대해 특이성을 갖는 ｃｔｌ주의 생성
RU2728867C2 (ru) * 2011-04-20 2020-07-31 Де Реджентс Оф Де Юниверсити Оф Калифорния Способ совместного кондиционирования и хемоселекции за один цикл
US8895264B2 (en) * 2011-10-27 2014-11-25 Sangamo Biosciences, Inc. Methods and compositions for modification of the HPRT locus
WO2013122591A1 (en) 2012-02-16 2013-08-22 Hewlett-Packard Development Company, L.P. Radio resource management
EP3071687B1 (en) * 2013-11-22 2019-07-31 Cellectis Method of engineering chemotherapy drug resistant t-cells for immunotherapy
MX2018001776A (es) * 2015-08-11 2018-06-06 Cellectis Celulas para inmunoterapia modificadas geneticamente para dirigirse al antigeno cd38 y para la inactivacion del gen cd38.
WO2017126987A1 (ru) * 2016-01-18 2017-07-27 Анатолий Викторович ЗАЗУЛЯ Эритроциты для направленного транспорта лекарственного средства
HK1257668A1 (zh) 2016-02-19 2019-10-25 The Regents Of The University Of California 短发夹rna(shrna734)及其用於阳性选择和消除遗传修饰的细胞的用途
US20180140606A1 (en) * 2016-11-18 2018-05-24 Calimmune, Inc. In Vivo Chemoselection with Low Dose Thioguanine
EP4190339B1 (en) * 2017-07-18 2025-07-02 CSL Behring Gene Therapy, Inc. A modulatable switch for selection of donor modified cells

Also Published As

Publication number Publication date
JP7410856B2 (ja) 2024-01-10
US20220072046A1 (en) 2022-03-10
BR112020001132A2 (pt) 2020-07-21
ES2940681T3 (es) 2023-05-10
KR20200125574A (ko) 2020-11-04
EP4190339A1 (en) 2023-06-07
WO2019018491A1 (en) 2019-01-24
CN111343996A (zh) 2020-06-26
SG11202000428PA (en) 2020-02-27
AU2018304222A1 (en) 2020-02-20
JP2020528455A (ja) 2020-09-24
US20190054119A1 (en) 2019-02-21
CA3070258A1 (en) 2019-01-24
US10426798B2 (en) 2019-10-01
EP3654994B1 (en) 2022-12-28
US11213548B2 (en) 2022-01-04
EP4190339B1 (en) 2025-07-02
EP3654994A1 (en) 2020-05-27
US20200038444A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
ES2940681T3 (es) Un interruptor modulable para la selección de células modificadas donantes
JP6818720B2 (ja) カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法
Passeri et al. Tolerogenic IL-10-engineered dendritic cell-based therapy to restore antigen-specific tolerance in T cell mediated diseases
Ghosh et al. T-cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations
KR20200016954A (ko) 전신 면역억제가 불필요한 동종 이식편 내성
AU2016259368B2 (en) Method for combined conditioning and chemoselection in a single cycle
Sawada et al. Umbilical cord blood as an alternative source of reduced-intensity hematopoietic stem cell transplantation for chronic Epstein-Barr virus–associated t or natural killer cell lymphoproliferative diseases
CN115137752A (zh) 用于干细胞移植的方法
US20250242021A1 (en) Allogeneic t cells for treatment of hematological malignancies
US20250195650A1 (en) Methods and compositions for enhancing efficacy of therapeutic immune cells
Hannouneh et al. Cellular Therapies in Transplantation–Regulatory T Cell Therapies and Virus Specific Therapies
Alton et al. Progress and prospects: gene therapy clinical trials (part 2)
JP2002520262A (ja) Ｔリンパ球交換
Villa et al. Virotherapy as potential adjunct therapy for graft-vs-host disease
US20240218330A1 (en) Compositions for improving the transduction of cells by viral vectors
KR102908831B1 (ko) 의학 용도
Tiberghien et al. Gene transfer applied to the modulation of alloreactivity
Sweeney et al. Methotrexate exacerbates tumor progression in a murine model of chronic myeloid leukemia
Greiner et al. Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell
Song et al. Donor gdT Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation
HK40047175A (en) Medical uses
Himburg et al. Systemic Administration Of Pleiotrophin Induces Hematopoietic Stem Cell (HSC) Regeneration in vivo
Kolb et al. W Zhao, JJ Li, DY Cao et al.,“Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis" World Journal of Gastroenterology, vol. 18, no. 10, pp. 1048–1058
WO2013128022A1 (en) Method for preventing or treating a hepatitis c virus infection or a hepatitis b virus infection by administration of suicide gene-modified lymphocytes